Literature DB >> 12588648

Multivalent Galalpha1,3Gal-substitution makes recombinant mucin-immunoglobulins efficient absorbers of anti-pig antibodies.

Jining Liu1, Andrej Weintraub, Jan Holgersson.   

Abstract

Hyperacute organ xenograft rejection can be prevented by removing anti-pig antibodies by extracorporeal absorption prior to transplantation. A novel recombinant absorber of anti-pig antibodies was developed by fusing the cDNA encoding the extracellular part of a mucin-type protein, P-selectin glycoprotein ligand-1, with an antibody Fc fragment cDNA, which upon coexpression with the porcine alpha1,3 galactosyltransferase carried the xenogeneic epitope, Galalpha1,3Gal (Liu J., Qian Y., Holgersson J., Transplantation 1997, 63, 1673-1682). The biochemical characterization of the mucin/Ig and its absorption efficacy compared with that of porcine thyroglobulin and Galalpha1,3Gal-conjugated beads are reported. The carbohydrate portion of the mucin/Ig constituted 43% of its molecular weight and the majority of the Galalpha1,3Gal epitopes were O-linked as assessed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and Western blotting following N-glycosidase F digestion. Gas chromatography-mass spectrometry of reduced and acetylated saccharides released by alpha-galactosidase treatment revealed that the fusion protein carried approximately 140 mol of terminal, alpha-linked galactose per mole protein. Based on the reduction in pig aortic endothelial cell cytotoxicity, Galalpha1,3Gal-substituted mucin/Igs on agarose beads were, on a carbohydrate molar basis, shown to be approximately 20 times more efficient than agarose-conjugated pig thyroglobulin, and approximately 5000 and 30,000 times more efficient than Galalpha1,3Gal-substituted agarose and macroporous glass beads, respectively. Structural features of the mucin backbone and its carbohydrate core saccharide chains determine the structural context, spatial orientation and spacing of Galalpha1,3Gal epitopes and are likely to explain the superior absorption efficacy of the recombinant mucin-type chimera.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12588648     DOI: 10.1034/j.1399-3089.2003.01144.x

Source DB:  PubMed          Journal:  Xenotransplantation        ISSN: 0908-665X            Impact factor:   3.907


  4 in total

1.  Recombinant Mucin-Type Fusion Proteins with a Galα1,3Gal Substitution as Clostridium difficile Toxin A Inhibitors.

Authors:  Reeja Maria Cherian; Chunsheng Jin; Jining Liu; Niclas G Karlsson; Jan Holgersson
Journal:  Infect Immun       Date:  2016-09-19       Impact factor: 3.441

2.  Identification of an anti-idiotypic antibody that defines a B-cell subset(s) producing xenoantibodies in primates.

Authors:  Jacqueline Fischer-Lougheed; Clare Gregory; Zena White; Irina Shulkin; Mirja Gunthart; Mary Kearns-Jonker
Journal:  Immunology       Date:  2007-10-03       Impact factor: 7.397

3.  Human gastric mucins differently regulate Helicobacter pylori proliferation, gene expression and interactions with host cells.

Authors:  Emma C Skoog; Åsa Sjöling; Nazanin Navabi; Jan Holgersson; Samuel B Lundin; Sara K Lindén
Journal:  PLoS One       Date:  2012-05-01       Impact factor: 3.240

4.  Identification by mass spectrometry and immunoblotting of xenogeneic antigens in the N- and O-glycomes of porcine, bovine and equine heart tissues.

Authors:  Chunsheng Jin; Reeja Maria Cherian; Jining Liu; Heribert Playà-Albinyana; Cesare Galli; Niclas G Karlsson; Michael E Breimer; Jan Holgersson
Journal:  Glycoconj J       Date:  2020-06-15       Impact factor: 2.916

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.